The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
The Upper Rhine Immunology (URI) meeting will bring together researchers from Strasbourg, Basel, Karlsruhe and Freiburg who will present their recent work and expert views in the fields of adaptive and innate immunity, signaling and immune response, hematopoiesis, immunodeficiency, inflammation and disease, as well as immunotherapy.
A big THANK YOU to all the attendees joining this year’s SFB1160 PPII conference, for all the amazing talks and the lively discussions, we are very happy to have had you all here in Freiburg in presence !
The scientific committee had put together a wonderful 3-day programme that attracted more than 260 participants to listen to and discuss exciting scientific talks.
On behalf of the boards of the CRC 1160 – IMPATH and the Center for Chronic Immunodeficiency (CCI), we are delighted to invite you to participate to the “From Paradigms to Paradoxes in Immunity and Immunopathology (PPII) International Conference” – to be held in Freiburg from 06-08 October 2022.
Registration and abstract submission closed!
van Otterdijk, S. D., H. Klett, M. Boerries, and K. B. Michels. 2023. The impact of pre-pregnancy folic acid intake on placental DNA methylation in a fortified cohort. FASEB J 37: e22698. doi: 10.1096/fj.202200476RR.
Rapp, J., M. Jung, R. F. U. Klar, J. Wolf, J. Arnold, O. Gorka, O. Gross, C. Lange, H. Agostini, G. Schlunck, and F. Bucher. 2022. STAT3 signaling induced by IL-6 family cytokines modulates angiogenesis. J Cell Sci. :jcs.260182. doi: 10.1242/jcs.260182.
Ruckert, T., G. Andrieux, M. Boerries, K. Hanke-Muller, N. M. Woessner, S. Doetsch, C. Schell, K. Aumann, J. Kolter, A. Schmitt-Graeff, M. Schiff, L. M. Braun, E. Haring, S. Kissel, B. A. Siranosian, A. S. Bhatt, P. Nordkild, J. Wehkamp, B. A. H. Jensen, S. Minguet, J. Duyster, R. Zeiser, and N. Kohler. 2022. Human beta-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med 14: eabp9675. doi: 10.1126/scitranslmed.abp9675.
Rush-Kittle, J., L. Gamez-Diaz, and B. Grimbacher. 2022. Inborn errors of immunity associated with defects of self-tolerance checkpoints: The CD28 family. Pediatr Allergy Immunol 33: e13886. doi: 10.1111/pai.13886.